Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.
Erasca's Naporafenib, combined with trametinib, demonstrates potential for durable efficacy in NRAS-mutant melanoma, addressing a critical unmet need after frontline immunotherapy.
IAG933 directly disrupts the YAP/TAZ-TEAD protein-protein interaction, leading to YAP eviction from chromatin and reduced Hippo-mediated transcription.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.